"Earnings This Strong, So Why Is the Stock Down?"... SK Biopharm Faces Test with 'Next Cenobamate'
Predicted impact: Medium
Strong Q3 earnings expectations already reported; the stock-pressure angle is commentary.
SK biopharmaceuticalsSK바이오팜
326030 · KOSPI · ₩326030 · SK바이오팜
₩77,800▲ ₩2,600 (3.46%)End-of-day · Oct 29, 2026 · End-of-day prices.
SK Biopharm Expected to Post Strong Q3 on Xcopri Growth; Target Price ₩155,000 Maintained – DS
Predicted impact: Low
Q3 earnings preview was already covered in the past 14 days; no surprise size given.
SK Biopharm earnings on track, Phase 3 resumption of Ojjaara in focus [Why Bio]
Predicted impact: Low
Earnings described as on track with no surprise; trial resumption is vague timing.
Also known as: SK biopharmaceuticals / SK바이오팜 / 326030 / KRX:326030
Source: KRX statistical information